An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
This extension II study allowed for further follow-up of the disease under treatment with imatinib mesylate and allow the participants to continue to receive imatinib mesylate.
Philadelphia Chromosome Positive CML
DRUG: imatinib mesylate
Overall Survival, Overall survival was defined as the number of events of death, expressed as a percentage, from the start of treatment to death, due to any reason., From first dose until death of the patient, up to 14 years.|Overall Survival (by Month), Overall survival was defined as the time between start of treatment and death due to any reason. Overall survival for the participants was calculated by Kaplan-Meier estimates per month. The time was censored at the date of last contact for participants who discontinued treatment and were in survival follow-up., From first dose until death of the patient, up to 14 years.
This extension II study allowed for further follow-up of the disease under treatment with imatinib mesylate and allow the participants to continue to receive imatinib mesylate.